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Therapy of feline diabetes mellitus 
Prof. Dr. Claudia Reusch, Dipl ECVIM-CA 
Clinic for Small Animal Internal Medicine, University of Zurich, Switzerland 
 
The primary goal is to eliminate the clinical signs of diabetes, such as polyuria, polydipsia, 
polyphagia and weight loss by good glycemic control, to prevent complications (e.g. 
hypoglycemia, DKA) and thereby enable a good quality of life.  Early treatment and good 
glycemic control is important to increase the chance of diabetic remission. However, this 
issue requires special attention and one should remember that aggressive insulin therapy and 
aiming for normal or near normal blood glucose concentrations increases the risk of 
hypoglycemia. We routinely discuss the possibility of diabetic remission with owners of 
newly diagnosed diabetic cats, however, we do not stress remission as the major treatment 
goal.  
The administration of insulin is the most important part of the treatment regimen in diabetic 
cats and should be initiated as soon as possible after the diagnosis is established. Insulin 
therapy is superior to the currently available oral hypoglycemic drugs to reverse the negative 
effects of glucose toxicity and to increase the chance of diabetic remission. In overt diabetes 
mellitus, dietary management alone is insufficient and may lead to deterioration of the disease 
and potentially to DKA. Diet, however, is an important part of the treatment and the cat 
should be fed a low-carbohydrate-high-protein diet. According to the AAHA Diabetes 
Management Guidelines, the carbohydrate content should be as low as the cat will eat 
(Rucinsky et al, 2010). 
In the last two decades, the manufacture and development of insulin for human use has 
undergone revolutionary changes, which have had important implications in veterinary 
medicine. First, insulins derived from animal sources are being more and more replaced by 
recombinant human preparations and will eventually disappear from the market. Although 
there are differences in the amino acid sequence, human insulins (and their analogues) are 
fortunately biologically active in cats. Second, insulin preparations for human use containing 
40-IU/ml have largely been replaced by 100-IU/ml insulins. It is important that owners 
understand the difference, because two insulin preparations for veterinary use (Caninsulin® 
and ProZinc®) are supplied as 40-IU/ml and using the wrong syringe size would lead to 
substantial dosing errors. Third, new classes of insulins called insulin analogues have been 
developed. They were designed to improve the pharmacodynamic properties of insulin and 
render insulin absorption or insulin delivery to tissues more predictable. The currently 
available insulin analogues are certainly just the start of a whole new area of insulin 
preparations.  
Cats are unpredictable in their response to insulin and none of the insulin preparations 
described above are routinely effective to control the disease. We nowadays start treatment in 
diabetic cats with insulin glargine (Lantus®), PZI (ProZinc®) would also be a good first 
choice. Both, insulin glargine and PZI are recommended by the AAHA Diabetes Management 
Guidelines (Rucinsky et al, 2010). If a diabetic cat is well regulated with Caninsulin®, there 
is no reason to switch it to one of the other insulins preparations. Nearly all cats require 
insulin twice daily, therefore, we always start with BID administration. The initial dose in cats 
weighing < 4 kg is 1 IU/cat BID, and in cats weighing > 4 kg it is usually 1.5 IU/cat (-2.0 
IU/cat) BID. In cats with a blood glucose concentration < 350 mg/dl (20 mmol/l) at the time 
of diagnosis, no more than 1 U/cat BID is given, independent of the body weight. The starting 
dose should not exceed 2.0 IU/cat BID, even in a very large cat. It is better to start 
conservatively (e.g. maximum dose of 1.5 IU/cat BID), than to risk hypoglycaemia during the 
first few days which may lead to owner frustration and potentially cessation of therapy. Very 
small cats (< 2 kg) are started on no more than 0.5 IU/cat BID. One of the most important 
periods in the owner’s care of a diabetic pet is the time during which the veterinarian teaches 
the technical aspects of the treatment and explains the monitoring protocol. The owner should 
be instructed to mix the insulin correctly: the manufacturer of ProZinc® recommends gently 
rolling of the vial, whereas Caninsulin® should be vigorously shaken. Lantus® (and 
Levemir®) are clear solutions and need no mixing. After the initial work-up, the cat is 
discharged with insulin, syringes, diet and, if needed, treatment for any concurrent disease 
(e.g. urinary tract infection). We inform the owner about the fact that during the next 3 
months, frequent re-evaluations and close monitoring are needed.  Re-evaluations are 
scheduled as a minimum after weeks 1, 2-3, 6-8, 10-12, 14-16 and then approximately every 4 
months. Additional appointments may be necessary in some cats.  It usually takes between 
one and three months until adequate glycemic control is achieved, and it is also during the 
first three months that the likelihood of diabetic remission is greatest. The latter should not be 
over-looked, as serious hypoglycemia may occur. We also introduce the general concept of 
home-monitoring after initial work-up, and the technique is taught after 2 – 3 weeks. Clinical 
signs of diabetes usually resolve when blood glucose concentrations can be kept below the 
renal threshold, ideally the lowest glucose concentration (glucose nadir) should be between 80 
and  140 mg/dl (4.5 – 7.8 mmol/l), the highest glucose concentration between 180 and 270 
mg/dl (10 – 15 mmol/l). At each re-evaluation, the owner is questioned about his/her opinion 
on the cats overall health, water intake, urine output, a thorough physical examination is 
performed, body weight recorded and a serial blood glucose curve is generated. Fructosamine 
measurement may also be informative. If glycemic control is considered unsatisfactory, the 
insulin dose is increased in steps of 0.5 IU/cat per injection. It is possible that the insulin dose 
has to be increased several times until a reaction (clinically and with regard to blood glucose 
concentration) is seen. We usually make dose changes no more often than every 5 to 7 days. It 
is also possible that the type of insulin has to be changed. If duration of action is too short, a 
longer acting insulin should be used and vice versa. As mentioned above, Caninsulin® 
usually has a shorter duration of action than ProZinc® and Lantus®; in some cats, ProZinc® 
may have a longer duration of action than Lantus®, although there is variability between cats. 
Levemir® seems to have a slightly longer duration of action than Lantus®. However, there 
are substantial differences between diabetic cats and insulin preparation and insulin doses 
have to be adapted according to the need of the individual cat. If hypoglycemia is noted at any 
time, the insulin dose should be reduced and another re-evaluation scheduled soon thereafter. 
Most diabetic cats can be adequately controlled with insulin doses between 0.5 and 3 IU/cat 
BID, i.e. usually with less than 1.0 IU/kg BID.  If insulin requirement increases to 1 IU/kg 
BID or more without achieving adequate control, further work-up for any disease causing 
insulin resistance is indicated.  
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